Univercells Technologies, a provider of novel biomanufacturing technologies for flexible and scalable advanced therapies and vaccine production, has completed €2 million expansion of its Nivelles, Belgium site. The investment aims to deliver greater support and supply chain security to biomanufacturers.
 
Nivelles site expansion began in December 2020 when the company doubled its overall footprint. The initial focus was on expanding warehouse storage as well as the ISO 8 clean room space, greatly increasing capacity for bioreactors and related single use assemblies. This was followed by the remodeling the office and work spaces to offer a flexible and modern workplace. The expansion also allows customers to come on site to work in one of the new ‘hands-on’ bioprocess training suites for guidance and support.
 
“Nivelles is a legacy site where we first opened our cleanrooms in March of 2019. We are investing in this site to maximize our manufacturing capabilities and core competencies for customers, while better supporting our employees,” said Mathias Garny, CEO of Univercells Technologies. “Our existing footprint has been increased by 100%, netting a 3x increase in production capacity. We have been able to insource the critical steps of preparation and assembly of our proprietary fixed bed, the key to the superior performance of all our scale-X™ bioreactors.”
 
Gareth Crothers, Head of Manufacturing & Supply at Univercells Technologies, shares, “We believe that providing a quality work environment for our valued employees is critical to providing the best support to our customers. This investment is a key step to maintaining our highly competitive bioreactor and manifold lead-times of under a month for standard items and maintaining high on time shipment while demand grows. And we will continue to take steps to evolve with the market and ensure security of supply of our capital equipment products, as well as the components needed for our consumable products.”